Covalent drugs have the potential to target previously ‘undruggable proteins’, and have advantages such as prolonged action, enhanced potency, and lower dosing requirements.
Key highlights of the poster include:
- a background to covalent small molecules and their advantages
- the application of site-specific covalent hit ID by peptide RapidFire mass spectrometry (RF/MS)
- comparison with a global high throughput intact protein RF/MS approach
- the benefits of using a combined approach to identify the most promising compounds
